Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | IKBKB | O14920 | 1/20 | 0.46 |
| ▸ | CHUK | O15111 | 1/20 | 0.46 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3970904 | 0.90 | CA12 (0.69) | TSHRNPSR1CA12CA2CA9 | |
| SCHEMBL3974097 | 0.83 | SIGMAR1 (0.69) | ALDH1A1SIGMAR1NEK1KMT2A | |
| SCHEMBL3143577 | 0.82 | NPSR1 (0.70) | TSHRNPSR1CA12CA2CA9 | |
| SCHEMBL7506700 | 0.81 | SIGMAR1 (0.50) | TSHRNPSR1CA12CA2CA9 | |
| SCHEMBL1348425 | 0.81 | TSHR (0.73) | TSHRNPSR1CA12CA2CA9 | |
| SCHEMBL6130639 | 0.81 | CA12 (0.81) | TSHRNPSR1CA12CA2CA9 | |
| SCHEMBL7014515 | 0.80 | CA12 (0.62) | TSHRCA12CA2CA9ALDH1A1 | |
| SCHEMBL7028080 | 0.79 | TSHR (0.71) | TSHRNPSR1CA12CA2CA9 | |
| SCHEMBL19152453 | 0.79 | TSHR (0.71) | TSHRNPSR1CA12CA2CA9 | |
| SCHEMBL3327488 | 0.79 | TSHR (0.71) | TSHRNPSR1CA12CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1301515-B1 | NON-GENOTOXIC METALLOPORPHYRINS AS SYNTHETIC CATALYTIC SCAVENGERS OF REACTIVE OXYGEN SPECIES | EUKARION INC (US) | 2005-01-19 | — | — | EP | claimed |
| US-20030212067-A1 | Matrix metalloprotease inhibitors | CASTELHANO ARLINDO LUCAS (US) | 2003-11-13 | — | — | US | claimed |
| CN-1173170-A | Matrix metalloprotease inhibitors | SYNTEX INC (US) | 1998-02-11 | — | — | CN | claimed |
| EP-0793643-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1997-09-10 | — | — | EP | claimed |
| WO-1996016027-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1996-05-30 | — | — | WO | claimed |
| US-7495040-B2 | Actinic ray curable composition, image forming method using the same and ink-jet recording apparatus using the same | KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) | 2009-02-24 | — | — | US | disclosed |
| US-20080012918-A1 | Actinic Radiation Curable Ink-Jet Ink, And Image Forming Method And Ink-Jet Recording Apparatus Using The Same | KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20050196697-A1 | Actinic ray curable composition, image forming method using the same and ink-jet recording apparatus using the same | KONICA MINOLTA MEDICAL & GRAPHIC, INC. | 2005-09-08 | — | — | US | disclosed |
| US-20050165123-A1 | Actinic ray curable composition, image forming method using the same and ink-jet recording apparatus using the same | KONICA MINOLTA MEDICAL & GRAPHIC, INC. | 2005-07-28 | — | — | US | disclosed |
| US-6855719-B1 | Imidazo[1,2-A]pyridine and pyrazolo[2,3-A]pyridine derivatives | ASTRAZENECA AB (SE) | 2005-02-15 | — | — | US | disclosed |
| CN-1174981-C | Imidazo [1, 2-A ] pyridine and pyrazolo [2, 3-A ] pyridine derivatives | — | 2004-11-10 | — | — | CN | disclosed |
| US-20030212067-A1 | Matrix metalloprotease inhibitors | CASTELHANO ARLINDO LUCAS (US) | 2003-11-13 | — | — | US | disclosed |
| US-6579890-B1 | Matrix metalloprotease inhibitors | SYNTEX (U.S.A.) INC. | 2003-06-17 | — | — | US | disclosed |
| CN-1370163-A | Imidazo [1,2-A] pyridine and pyrazolo [2,3-a] pyridine derivatives | ASTRAZENECA AB (SE) | 2002-09-18 | — | — | CN | disclosed |
| EP-1214318-A1 | IMIDAZO[1,2-A]PYRIDINE AND PYRAZOLO[2,3-A]PYRIDINE DERIVATIVES | AstraZeneca AB (SE) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001014375-A1 | IMIDAZO[1,2-A]PYRIDINE AND PYRAZOLO[2,3-A]PYRIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-03-01 | — | — | WO | disclosed |
| US-6037472-A | FOR TREATING DISEASE-STATES CHARACTERIZED BY EXCESSIVE ACTIVITY OF MATRIX METALLOPROTEASES SUCH AS RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTAL DISEASE, ABERRANT ANGIOGENESIS, TUMOR INVASION AND METASTASIS | SYNTEX (U.S.A.) INC. (US) | 2000-03-14 | — | — | US | disclosed |
| CN-1173170-A | Matrix metalloprotease inhibitors | SYNTEX INC (US) | 1998-02-11 | — | — | CN | disclosed |
| EP-0793643-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1997-09-10 | — | — | EP | disclosed |
| WO-1996016027-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1996-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212067-A1 | Matrix metalloprotease inhibitors | MMP7, MMP1, MMP3 | TSHR 4556/4885NPSR1 2293/4885CA12 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.